Korean researchers have developed an artificial intelligence (AI) model that can accurately predict the prognosis and ...

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.

Cellis is preparing to take its lead candidate into the clinic after seeing durable complete remissions in solid-tumor models. Drug developers have struggled to translate the exceptional efficacy ...

Aptevo Therapeutics (APVO) provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the ...

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a ...

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...

Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer.

The complexity of the TME in vivo limits the conclusions that can be drawn from in vitro models of cancer progression and therapy response. Optimizing cell culture models to mimic the TME is vital to ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

LAE120 shows robust tumor inhibitory activity across various xenograft models such as MDA-MB-436 and ... ovarian cancer and PD-1/ PD-L1 drug-resistant solid tumors. LAE002 (afuresertib) is a ...